ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
1. 7ÔÂ25ÈÕ£¬¾¢·½Ò½Ò©Ðû²¼GFH375/VS-7375£¨¿Ú·þKRAS G12DÒÖÖÆ¼Á£©»ñµÃÃÀ¹úFDAÊÚÓè¿ìËÙͨµÀ×ʸñ£¬ÓÃÓÚKRAS G12DÍ»±ä¾Ö²¿ÍíÆÚ»ò×ªÒÆÐÔÒÈÏÙµ¼¹ÜÏÙ°©£¨PDAC£©µÄÒ»Ïß¼°ºóÏßÖÎÁÆ¡£GFH375ÏÖÔÚÒÑÔÚÖйú½øÈë2ÆÚÑо¿£»GFH375/VS-7375ÔÚÃÀ¹ú¿ªÕ¹µÄ1/2aÆÚÑо¿Óɾ¢·½ÏàÖúͬ°éVerastem OncologyÓÚ½ñÄêÆô¶¯Íƽø¡£
2. 7 Ô 25 ÈÕ£¬NMPA ¹ÙÍøÏÔʾ£¬Ñï×Ó½Ò©ÒµÉ걨µÄ 1 ÀàÐÂÒ©¡¸ÑÎËáÍ×ŵ´ï·ÇƬ¡¹»ñÅúÉÏÊУ¬ÓÃÓÚÖÎÁÆÖÎÁƲªÆð¹¦Ð§Õϰ¡£ÑÎËáÍ×ŵ´ï·ÇƬ£¨ÔøÓÃÃû£ºÓÅ¿ËÄÇ·Ç£©ÊÇÒ»¿î¸ßЧºÍ¸ßÑ¡ÔñÐ﵀ 5 ÐÍÁ×Ëá¶þõ¥Ã¸£¨PDE5£©ÒÖÖÆ¼Á¡£
3. 7ÔÂ25ÈÕ£¬CDE¹ÙÍøÏÔʾ£¬¿µ·½ÉúÎïµÄÒÀÎÖÎ÷µ¥¿¹ÐÂ˳Ӧ֢ÉÏÊÐÉêÇëÒÑ»ñÊÜÀí¡£Æ¾Ö¤Æä×¢²áÐÔÁÙ´²Ñо¿Ð§¹û£¬ÍƲâ´Ë´ÎÉ걨µÄ˳Ӧ֢Ϊ£ºÁªºÏ»¯ÁÆÒ»ÏßÖÎÁÆÍíÆÚÁÛ×´·ÇСϸ°û·Î°©£¨sq-NSCLC£©¡£
4. 7ÔÂ25ÈÕ£¬CDE¹ÙÍøÏÔʾ£¬µÚÒ»Èý¹²Ó밢˹Àû¿µÅäºÏ¿ª·¢µÄµÂÇúÍ×Öéµ¥¿¹±»ÄÉÈëÄâÓÅÏÈÉóÆÀÐÐÁУ¬ÓÃÓÚHER2ÑôÐÔÈéÏÙ°©»¼Õßи¨ÖúÖÎÁÆ¡£µÂÇúÍ×Öéµ¥¿¹ÒÑÔÚÎÒ¹ú»ñÅúÁË4Ïî˳Ӧ֢£¬ÆäÖÐÁ½ÏîÊÇÈéÏÙ°©Ïà¹ØË³Ó¦Ö¢¡£
1. 7ÔÂ24ÈÕ£¬ÅµÎ´ÉúÎïÐû²¼Íê³ÉB1ÂÖÊýÍòÍòÔªÈÚ×Ê¡£±¾ÂÖÈÚ×ÊÓɺ£ÄÚ×ÅÃû»ú¹¹²©Í¨×ÊÔ´¡¢Îý´´Í¶ÒÔ¼°×¿Ô½ÃÀ¼ÑÅäºÏͶ×Ê£¬×ʽð½«Ö÷ÒªÓÃÓÚÍÆ½ø½¹µã¹ÜÏßµÄÁÙ´²Ò»¡¢¶þÆÚÑо¿¡£¹«Ë¾×Ô½¨ÉèÒÔÀ´£¬Ê¼ÖÕÉî¸ûÖ×ÁöÔçÆÚÖÎÁÆÁìÓò£¬×¨×¢ÓÚÈ«ÇòÁìÏȵÄFirst-in-ClassºËËáÒ©ÎïÑз¢£¬Òѹ¹½¨º¸ÇHPVѬȾÏà¹Ø¼²²¡¡¢¸Î°©µÈÖ×ÁöÁìÓòµÄÁ¢Òì¹ÜÏߣ¬ÆäÖнø¶ÈÁìÏÈÏîÄ¿ÒÑÍÆ½øÖÁÁÙ´²¶þÆÚ½×¶Î¡£
1. 7ÔÂ23ÈÕ£¬À´×ÔҮ³´óѧ/Fred HutchÖ×ÁöÖÐÐĵÄAaron RingÍŶӵĴ÷ÒÔÀÕ²©Ê¿ºÍÇØ¿²©Ê¿µÈÈË£¬ÓëHarriet KlugerÍŶӣ¬ÔÚNatureÔÓÖ¾ÉÏÏàÖú½ÒÏþÁËÌâΪHumoral determinants of checkpoint immunotherapyµÄÎÄÕ£¬½ÏΪϵͳÐÔµØÌ½Ë÷Á˰ÐÏòÉøÍ¸ÂѰ×ÓëĤÂѰ׵Äautoantibody/AAb£¨ÒÔϼò³ÆÎª×ÔÉí¿¹Ì壩¶ÔPD1/CTLA4Ö×ÁöÃâÒßÁÆ·¨Ð§¹ûµÄÓ°Ïì¡£
[1] Dai, Y., Aizenbud, L., Qin, K. et al. Humoral determinants of checkpoint immunotherapy. Nature (2025). https://doi.org/10.1038/s41586-025-09188-4